Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (plasma cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 3 Parkinson's papers of 1,731 | 0.82 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3857
Sealed predictions
- CD79A in dopamine neurons, braak-0.44 (p 0.237) → -0.11 (p 0.787)receipt 3863
Swarm cases
receipt 3863: CD79A in dopamine neurons, braak
- power
- full sample -0.27 (p 0.285, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.306, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.135, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.18, sign flips 0; without severely affected donors -0.27 (p 0.285, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.65 (p 0.0036, n 18) vs -0.27 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD79A in dopamine neurons.
case closed: every proposal failed a challenge.
Receipts
loading the receipts